Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

indium In 111-DOTA-girentuximab

A radioimmunoconjugate comprised of the chimeric monoclonal antibody girentuximab conjugated with the gamma-emitting radioisotope indium In 111. Indium In 111-DOTA-girentuximab binds to G250, allowing the localization of G250-expressing tumor cells using gamma scintigraphy. Found in the majority of renal cell carcinomas (RCCs), G250 or carbonic anhydrase isozyme IX (CA IX) is a cell surface tumor-associated antigen (TAA).

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	111-indium labeled chimeric monoclonal antibody G250 indium In 111 chimeric monoclonal antibody G250

indium In 111-DOTA-girentuximab

Search NCI's Drug Dictionary